Endothelial USP2a-METTL16 loop potentiates IL-6 signaling via m

Summary

The study identifies a self-reinforcing endothelial USP2a–METTL16 loop that amplifies IL-6-driven pulmonary vascular remodeling. Endothelial-specific Usp2a deletion or pharmacologic USP2a inhibition (ML364) mitigated experimental pulmonary hypertension, establishing this axis as a therapeutic target.

Key Findings

• USP2a is upregulated in lung tissues from PH patients, preclinical PH models, and IL-6–stimulated endothelial cells.
• Endothelial-specific Usp2a deletion and pharmacologic inhibition with ML364 alleviate experimental PH manifestations.
• USP2a deubiquitinates METTL16, preventing its degradation; METTL16 in turn increases USP2a expression via eIF3a/eIF3b interactions, forming a self-reinforcing loop.

Clinical Implications

Targeting USP2a pharmacologically (e.g., ML364-like inhibitors) or disrupting USP2a–METTL16 stabilization could emerge as a novel disease-modifying strategy in pulmonary hypertension alongside current vasodilators.

Limitations

• The abstracted results are preclinical; no human interventional data are presented.
• Downstream m6A-related mechanisms are truncated in the abstract, limiting detailed insight into terminal effectors.
• Safety, specificity, and pharmacokinetics of USP2a inhibition in vivo require further evaluation.

Future Directions

Define the full downstream transcriptomic/m6A program in PH endothelium, optimize selective USP2a inhibitors, and evaluate efficacy/safety in large-animal PH models and early-phase human trials.